# EDGAR Filing Document

**Accession Number:** 0000010795
**File Stem:** 0001628280-26-024472
**Filing Date:** 2026-4
**Character Count:** 10358
**Document Hash:** 6bd74c0f02c0c260534cf2cd63336f4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-024472.hdr.sgml**: 20260409

**ACCESSION NUMBER**: 0001628280-26-024472

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260406

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260409

**DATE AS OF CHANGE**: 20260409

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BECTON DICKINSON & CO
- **CENTRAL INDEX KEY:** 0000010795
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 220760120
- **STATE OF INCORPORATION:** NJ
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04802
- **FILM NUMBER:** 26851843

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BECTON DR
- **CITY:** FRANKLIN LAKES
- **STATE:** NJ
- **ZIP:** 07417-1880
- **BUSINESS PHONE:** 2018476800

**MAIL ADDRESS:**
- **STREET 1:** ONE BECTON DR
- **CITY:** FRANKLIN LAKE
- **STATE:** NJ
- **ZIP:** 07417

?xml version='1.0' encoding='ASCII'? bdx-20260406

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT PURSUANT TO**

**SECTION 13 OR 15(D) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported) April 6, 2026**

---

| |
|:---|
| **BECTON, DICKINSON AND COMPANY** |
| (Exact Name of Registrant as Specified in Its Charter) |
| **New Jersey** |
| (State or Other Jurisdiction of Incorporation) |

---

---

| | | | |
|:---|:---|:---|:---|
| **001-4802** | **001-4802** | **001-4802** | **22-0760120** |
| (Commission File Number) | (Commission File Number) | (Commission File Number) | (IRS Employer Identification No.) |
| **1 Becton Drive,** | **Franklin Lakes,** | **New Jersey** | **07417-1880** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

---

| | |
|:---|:---|
| **(201)**  | **847-6800** |
| (Registrant's Telephone Number, Including Area Code) | (Registrant's Telephone Number, Including Area Code) |
| **N/A** | **N/A** |
| (Former Name or Former Address, if Changed Since Last Report) | (Former Name or Former Address, if Changed Since Last Report) |

---

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of Each Class</u>** | **<u>Trading Symbol</u>** | **Name of each exchange on** <br>**<u>which registered</u>** |
| Common stock, par value $1.00 | BDX | New York Stock Exchange |
| 1.900% Notes due December 15, 2026 | BDX26 | New York Stock Exchange |
| 1.208% Notes due June 4, 2026 | BDX/26A | New York Stock Exchange |
| 1.213% Notes due February 12, 2036 | BDX/36 | New York Stock Exchange |
| 3.519% Notes due February 8, 2031 | BDX31 | New York Stock Exchange |
| 3.828% Notes due June 7, 2032 | BDX32A | New York Stock Exchange |

---

------

---

| | |
|:---|:---|
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| Emerging growth company  | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

------

**ITEM 5.02 &nbsp;&nbsp;&nbsp;&nbsp;DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.** 

On April 6, 2026, Richard E. Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company ("BD"), informed BD of his intention to retire. Mr. Byrd will remain in his role through June. BD intends to name a successor to Mr. Byrd prior to his retirement date.

**ITEM 7.01.&nbsp;&nbsp;&nbsp;&nbsp;REGULATION FD DISCLOSURE.**

On April 9, 2026, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

------

**ITEM 9.01&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit <u>[99.1](bdipressreleasedraft_vfinal.htm)</u>&nbsp;&nbsp;&nbsp;&nbsp; Press release dated April 9, 2026 which is furnished pursuant to Item 7.01.

Exhibit 104&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Registrant)

---

| | |
|:---|:---|
| By: | /s/ Stephanie M. Kelly |
|  | Stephanie M. Kelly |
|  | Chief Securities and Governance Counsel, Corporate Secretary |

---

Date: April 9, 2026

## Exhibit 99.01

NEWS RELEASE ![image_0.jpg](image_0.jpg)

**Rick Byrd to Retire from BD**

**FRANKLIN LAKES, N.J. (April 9, 2026)** – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD.

Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joining BD in 2004, Byrd held various leadership and engineering positions across the medical device and advanced technology sectors.

"Over his long career, Rick has led his teams to deliver meaningful results for BD – strengthening our portfolio, elevating our operational rigor and advancing BD's role as a global healthcare leader," said Tom Polen, chairman, CEO and president of BD. "Rick has driven impact across multiple segments, including expanding BD's leadership in Vascular Access Management, advancing our 'One-Stick Hospital Stay' vision and leading critical manufacturing scale-up efforts during the COVID-19 pandemic. We thank Rick for his many contributions to BD and wish him all the best in his retirement."

Byrd will remain in his role through June. BD intends to name a successor prior to Byrd's retirement date.

"What has inspired me most throughout my time at BD is the people – the teams who show up every day committed to driving the future of care and improving outcomes for patients everywhere," Byrd said. "I'm incredibly proud of the meaningful work we've accomplished together and am confident that BD will continue to deliver on its purpose of advancing the world of health."

\# \# \#

**About BD**<br>BD is one of the world's largest pure-play medical technology companies with a Purpose of *advancing the world of health™* by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.

------

---

| | |
|:---|:---|
| **Contacts:** |  |
| <u>Media</u> | <u>Investors</u> |
| Megan Dubrowski<br>Senior Director, Executive Communications<br>Megan.Dubrowski@bd.com | Shawn Bevec <br>SVP, Investor Relations<br>Investor_Relations@bd.com  |

---

<br>